Source: PRWeb
Jeeva Clinical Trials is revolutionizing drug development by integrating AI and automated workflows into clinical trials, significantly reducing the time and cost of bringing treatments to market. Led by Dr. Harsha Rajasimha, the platform emphasizes efficiency and broadens participant diversity, addressing ethical AI use while enhancing patient recruitment and data management. This innovative approach is streamlining research, making it more efficient and reflective of the diverse patient populations it aims to serve.
MANASSAS, Va., March 12, 2024 /PRNewswire-PRWeb/ — Artificial intelligence (AI) is reshaping drug development and patient care, offering groundbreaking potential. Jeeva Clinical Trials is at the forefront of this shift, addressing the healthcare industry’s need for more efficient, inclusive, and compliant clinical trials. Led by Dr. Harsha Rajasimha, Jeeva is embedding AI within its clinical trial framework to automate and accelerate the research workflows and patient outcomes.
“The integration of AI is not just a leap forward; it is a necessary evolution to address the complex challenges of today’s clinical trials,” said Rajasimha. “AI stands at the intersection of speeding the timelines of drug development, ensuring diverse participants inclusion, and optimizing financial resources.”
Enhancing Efficiency with AI
The traditional clinical trial process is often encumbered by time-consuming manual processes including patient screening, enrollment, site monitoring, clinical data management, patient engagement and retention, biostatistical data analysis, and reporting or preparation of publications. This has resulted in clinical R&D for certain medical conditions taking upwards of a decade to complete. AI stands to revolutionize this by digitizing and automating data flow, which can cut down the drug development timeline significantly. (1) By streamlining data management, AI reduces the manual effort and potential for human error, facilitating a faster path for treatments from bench to bedside. (2) This not only shortens the development timeline but also has the potential to lower the costs associated with clinical research.
Navigating Ethical and Practical Concerns
The ethical and practical implications of AI are complex and require meticulous consideration. Data privacy, the potential for bias in AI algorithms, and the importance of human judgment in decision-making are chief among the concerns that Jeeva Clinical Trials is proactively addressing. Ensuring that AI systems are transparent (3) and that data used is unbiased is a priority, as is the commitment to upholding the human element in clinical decision-making. Good Clinical Practice (GCP) and other regulatory guidance documents continue to serve as a reference in making cautious decisions about the use of AI as an enabling powerful tool in clinical research.
Economic Implications of AI Integration
AI has a profound impact on the economics of clinical trials. Through automation and efficient data management, AI can lead to substantial cost savings (4), enabling resources to be redirected towards patient care and research innovation. This adoption does require initial investments in technology and expertise; however, the potential long-term cost savings and efficiencies are considerable. With prudent investment and strategic planning, AI technology can yield a high return on investment for clinical trial processes.
Advancing DEIA Through Gen-AI
One of the critical challenges in clinical trials has been the historical underrepresentation of certain populations. Generative AI technology offers the tools to identify and engage a broader range of participants from various demographics, languages, and cultures, making trials more inclusive (5). By employing AI, Jeeva Clinical Trials is taking steps to reduce the historical barriers to trial participation for underrepresented groups, ensuring that medical advances benefit all sections of society equitably. Careful design and monitoring of AI systems ensure that the diversity in data sets is prioritized, promoting diversity, equity, inclusion, and accessibility (DEIA) in trial outcomes.
Jeeva Clinical Trials: Pioneering a Future of Inclusive, Efficient Healthcare
Jeeva Clinical Trials is dedicated to reshaping the landscape of clinical research by harnessing AI technology. The vision, as articulated by founder Dr. Harsha Rajasimha, is to build a future where clinical trials are powered by AI, making them more reflective of the populations they serve and where lifesaving treatments are developed more efficiently and made available swiftly to all who need them. Embracing the ideology that, “Clinical Trials require tremendous multidisciplinary human expertise and are not going to be entirely replaceable by AI.” As Dr. Rajasimha states, “Clinical Trials that are not powered by AI will be replaced by Clinical Trials that are,” and Jeeva is at the forefront of this transformative shift.
Over the last five years, Jeeva Clinical Trials has developed and commercialized a suite of cloud-based clinical trial management, patient engagement, and data management solutions and has unified all these tools into an efficient platform that operates at both the technical and functional modules of a clinical study workflow under one digital roof. This strong foundational platform is putting Jeeva in a unique position to reimagine the way clinical trials are designed and executed particularly by emerging and mid-market biopharmaceutical sponsors. This innovative platform brings together most elements of a patient-centric clinical trial management system that streamlines complex processes from start to finish under one login. Because the Jeeva eClinical platform already includes and integrates most components of a clinical trial operation such as protocol design and writing, site qualification and monitoring, patient screening and recruitment, and monitoring, clinical data management, biostatistical data analysis and reporting, it has opened up exciting new possibilities to capitalize on the generative AI and automation to enhance efficiency, quality, and compliance.
Thus, the differentiated AI-driven Jeeva platform under a single-login aims to become a “co-pilot” for clinical researchers while empowering seamless remote participation by patients.
About Jeeva Clinical Trials Inc. (“Jeeva”)
Founded by Dr. Harsha Rajasimha after a deeply personal experience, Jeeva’s mission to “Revolutionize Clinical Trials and Empower Outcomes” propels their differentiated platform with AI and workflow automation under one bundled subscription. Jeeva empowers global biopharmaceutical, medical device, and nutraceutical sponsors, simplifying patient engagement and evidence generation, achieving 70% greater efficiency in research. Trusted by prestigious organizations like Frantz Viral Therapeutics and George Mason University, their technology supports diverse study designs, from traditional to fully decentralized models, across disease areas including oncology and rare diseases. With empathy and determination, Team Jeeva has developed an innovative, efficient, and compliant platform that enables sponsors to conduct clinical trials more effectively, breaking down barriers and fostering a globally inclusive and diverse participant pool. This includes facilitating remote participation. Powered by AI and automation, Jeeva is leading a transformation in the life sciences industry, one clinical trial at a time. Discover more about how Jeeva is reimagining the future of clinical trials at https://jeevatrials.com/.
References
- Hayes-Mota, Guadalupe. “Council Post: AI Is Rapidly Transforming Drug Discovery.” Forbes, 29 Feb. 2024, http://www.forbes.com/sites/forbesbusinesscouncil/2024/02/29/ai-is-rapidly-transforming-drug-discovery/?sh=52bcbcb684b1. Accessed 8 Mar. 2024.
- Lingler, Nick. “Using AI to Accelerate Clinical Trials.” Deloitte United States, 24 Feb. 2022, https://www.deloitte.com/us/en/blog/health-care-blog/2022/using-ai-to-accelerate-clinical-trials.html.
- Pazzanese, Christina. “Ethical Concerns Mount as AI Takes Bigger Decision-Making Role.” Harvard Gazette, Harvard University, 2020, https://news.harvard.edu/gazette/story/2020/10/ethical-concerns-mount-as-ai-takes-bigger-decision-making-role/.
- Grover, Natalie, and Martin Coulter. “Insight: Big Pharma Bets on AI to Speed up Clinical Trials.” Reuters, 22 Sept. 2023, http://www.reuters.com/technology/big-pharma-bets-ai-speed-up-clinical-trials-2023-09-22/.
- Prince, Dr Mesha Martinez, Moleen Madziva and Toni. “Health Equity Begins with Increasing Diversity in Clinical Research: AI Can Help.” MedCity News, 2 Oct. 2023, https://medcitynews.com/2023/10/health-equity-begins-with-increasing-diversity-in-clinical-research-ai-can-help/. Accessed 8 Mar. 2024.
